Coherus Oncology (CHRS) Receivables - Other (2013 - 2026)

Coherus Oncology has disclosed Receivables - Other across 6 years of filings, most recently posting $372000.0 for Q2 2026.

• In Q2 2026, Receivables - Other fell 99.68% year-over-year to $372000.0; the TTM figure through Jun 2026 stood at $372000.0 (down 99.68% YoY), while the FY2025 annual figure was $603000.0, down 94.52% from the prior year.
• Receivables - Other came in at $372000.0 for Q2 2026 at Coherus Oncology, down from $446000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $241.3 million in Q3 2025 to a low of $372000.0 in Q2 2026.
• Average Receivables - Other over 3 years is $57.2 million, with a median of $21.1 million recorded in 2024.
• Year-over-year, Receivables - Other soared 672.23% in 2025 and slumped 99.68% in 2026.
• Over 3 years, Receivables - Other stood at $11.0 million in 2024, then sank by 94.52% to $603000.0 in 2025, then tumbled by 38.31% to $372000.0 in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $372000.0 in Q2 2026, $446000.0 in Q1 2026, and $603000.0 in Q4 2025.